Cover Image

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA Objective: To estimate the 5-year budge...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ferrufino CP (Author), Munakata J (Author), Wei W (Author), Proudfoot C (Author), Kuznik A (Author), Boklage SH (Author), Chen C (Author)
Format:	Book
Published:	Dove Medical Press, 2018-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
by: Ferrufino CP, et al.
Published: (2019)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
by: Fournier M, et al.
Published: (2019)

CORRELATIONS BETWEEN SYSTEMIC THERAPY WITH CONVENTIONAL (SYNTHETIC) AND BIOLOGICAL DMARDS, RHEUMATOID ARTHRITIS AND PERIODONTAL INDICES OF CHRONIC PERIODONTITIS
by: Maria Alexandra Martu, et al.
Published: (2019)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020)

Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
by: M. J. H. Voshaar, et al.
Published: (2022)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
by: Pavel Kovalenko, et al.
Published: (2020)

Sarilumab‐induced cutaneous adverse event
by: Sayaka Sato, et al.
Published: (2022)

Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan
by: Der-Yuan Chen, et al.
Published: (2019)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
by: Vladimira Boyadzhieva, et al.
Published: (2018)

The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs)
by: Zahra Samimi, et al.
Published: (2020)

The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis
by: Weiyan Cai, et al.
Published: (2018)

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs
by: Alen Brkic, et al.
Published: (2022)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022)

Saudi cultural adaptation of the "compliance questionnaire of Rheumatology" for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
by: Roaa Aljohani, et al.
Published: (2021)

Disease Activity in Disease Modifying Anti-Rheumatic Drug (DMARD) Naïve Rheumatoid Arthritis Patients in A Subset of Karachi Population
by: Dr. Mehreen Inam Illahi, et al.
Published: (2024)

Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients
by: Sergio Ramirez-Perez, et al.
Published: (2021)

TNFα blockers and infectious risk in rheumatoid arthritis
by: S. Todesco, et al.
Published: (2011)

Efficacy of the cardiac glycoside digoxin as an adjunct to csDMARDs in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled trial
by: Nageh A. El-Mahdy, et al.
Published: (2024)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
by: Cynthia Said, et al.
Published: (2013)

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
by: Felice Rivellese, et al.
Published: (2020)

Influence of TNF-α inhibition on oxidative stress of rheumatoid arthritis patients
by: F. Cacciapaglia, et al.
Published: (2016)

Emerging intervention of antidepressant with DMARD in non-cancerous nociceptive persistent pain associated depression in FCA induced rheumatoid arthritic rats
by: Sudhakar Pachiappan, et al.
Published: (2021)

Ultrasound Detection of Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment
by: Anupama C. Nandagudi MSc, MRCP (UK), et al.
Published: (2014)

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
by: Nordal EB, et al.
Published: (2011)

Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs
by: E. Lubrano, et al.
Published: (2012)

An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis
by: Martin-Martin LS, et al.
Published: (2017)

Inadequate Dietary Diversity among Female Students in Southeast Sulawesi, Indonesia: Influences of Parental Education and Food Budget
by: Devi Savitri Effendy, et al.
Published: (2024)

DMOADs and DMARDs in the treatment of patients with joint and spine diseases
by: O. A. Shavlovskaya
Published: (2024)

Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis
by: F. R. Spinelli, et al.
Published: (2013)

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
by: R. Caporali, et al.
Published: (2011)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
by: Fragoulakis V, et al.
Published: (2015)

Influence on Effectiveness of Early Treatment with Anti-TNF Therapy in Rheumatoid Arthritis
by: Vicente Escudero-Vilaplana, et al.
Published: (2012)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
by: Delphine Dénarié, et al.
Published: (2017)

TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results
by: M. Fabris, et al.
Published: (2002)

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
by: Alexander Vugler, et al.
Published: (2022)